Search

Your search keyword '"Cappello, M."' showing total 865 results
Start Over Author "Cappello, M."
865 results on '"Cappello, M."'

1. A 1-year follow-up study on checkpoint inhibitor-induced colitis: results from a European consortium

Author

Mengoli, C., Aronico, N., Lepore, F., Broglio, G., Merli, S., Natalello, G., Alimenti, E., Scalvini, D., Muscarella, S., Agustoni, F., Pagani, A., Chiellino, S., Corallo, S., Musella, V., Cannizzaro, R., Vecchi, M., Caprioli, F., Gabbiadini, R., Dal Buono, A., Premoli, A., Locati, L.D., Buda, A., Contaldo, A., Schiepatti, A., Biagi, F., Morano, D., Cucè, M., Kotsakis, A., De Lisi, G., Lenti, M.V., Ribaldone, D.G., Borrelli de Andreis, F., Vernero, M., Barberio, B., De Ruvo, M., Savarino, E.V., Kav, T., Blesl, A., Franzoi, M., Gröchenig, H.P., Pugliese, D., Ianiro, G., Porcari, S., Cammarota, G., Gasbarrini, A., Spagnuolo, R., Ellul, P., Foteinogiannopoulou, K., Koutroubakis, I., Argyriou, K., Cappello, M., Jauregui-Amezaga, A., Demarzo, M.G., Silvestris, N., Armuzzi, A., Sottotetti, F., Bertani, L., Festa, S., Eder, P., Pedrazzoli, P., Lasagna, A., Vanoli, A., Gambini, G., Santacroce, G., Rossi, C.M., Delliponti, M., Klersy, C., Corazza, G.R., and Di Sabatino, A.

Published
2024
Full Text
View/download PDF

2. Golimumab improves health-related quality of life of patients with moderate-to-severe ulcerative colitis: Results of the go-care study

Author

Saibeni, S., Bezzio, C., Bossa, F., Privitera, A.C., Marchi, S., Roselli, J., Mazzuoli, S., Geccherle, A., Soriano, A., Principi, M.B., Viola, A., Sarpi, L., Cappello, M., D'Incà, R., Mastronardi, M., Bodini, G., Guerra, M., Benedetti, A., Romano, M., Cicala, M., Di Sabatino, A., Scaldaferri, F., De Rosa, T., Giardino, A.M., Germano, V., Orlando, A., and Armuzzi, A.

Published
2024
Full Text
View/download PDF

4. OC.04.7: A ONE-YEAR FOLLOW-UP STUDY ON CHECKPOINT INHIBITORINDUCED COLITIS: RESULTS FROM A EUROPEAN CONSORTIUM

Author

Lenti, M.V., primary, Broglio, G., additional, Ribaldone, D.G., additional, Schiepatti, A., additional, Vernero, M., additional, Cosentino, F., additional, Blesl, A., additional, Buda, A., additional, Croitoru, A., additional, Del Buono, A., additional, Aranzazu Jaurgeu, A., additional, Lasagna, A., additional, Carvalho, D., additional, Pugliese, D., additional, Langholz, E., additional, Dahl, E., additional, Savarino, E.V., additional, Agustoni, F., additional, De Andreis, F. Borrelli, additional, Caprioli, F., additional, Schaik, F., additional, Sottotetti, F., additional, Cammarota, G., additional, Ianiro, G., additional, Gröchenig, H.P., additional, Koutroubakis, I., additional, Geldolf, J., additional, Argyriou, K., additional, Foteinogiannopolou, K., additional, Bertani, L., additional, Lobaton Ortega, T., additional, Cappello, M., additional, Delliponti, M., additional, Demarzo, M.G., additional, Truyens, M., additional, Silvestris, N., additional, Ellul, J., additional, Cannizzaro, R., additional, Gabbiadini, R., additional, Pedrazzoli, P., additional, Spagnuolo, R., additional, Saglio, S., additional, Stroie, T.G., additional, Natalello, G., additional, Varallo, M., additional, La Torre, M.A., additional, Petrucci, C., additional, Klersey, C., additional, Corazza, G.R., additional, and Di Sabatino, A., additional

Published
2024
Full Text
View/download PDF

6. OC.07.2: ASSESSMENT OF VEDOLIZUMAB AND USTEKINUMAB IN ELDERLY (AVENUE) PATIENTS WITH CROHN'S DISEASE (CD): AN IG-IBD STUDY

Author

Viola, A., primary, Ventimiglia, M., additional, Sparacino, A., additional, D'Antonio, E., additional, Orlando, A., additional, De Vivo, S., additional, Pugliese, D., additional, Varca, S., additional, Scaldaferri, F., additional, Ribaldone, D.G., additional, Armandi, A., additional, Balestrieri, P., additional, Castiglione, F., additional, Savarino, E.V., additional, Cappello, M., additional, Viganò, C., additional, Mocci, G., additional, Allocca, M., additional, Principi, M.B., additional, Soriano, A., additional, Onali, S., additional, Bodini, G., additional, Riguccio, G., additional, Festa, S., additional, Bertani, L., additional, Checchin, D., additional, Caprioli, F., additional, and Fries, W., additional

Published
2024
Full Text
View/download PDF

13. Birds.

Author

Aspinall, V., primary, Cappello, M., additional, and Phillips, C., additional

Published
2019
Full Text
View/download PDF

20. The horse.

Author

Aspinall, V., primary, Cappello, M., additional, and Phillips, C., additional

Published
2019
Full Text
View/download PDF

24. Golimumab improves health-related quality of life of patients with moderate-to-severe ulcerative colitis: Results of the go-care study

Author

Saibeni, S., primary, Bezzio, C., additional, Bossa, F., additional, Privitera, A.C., additional, Marchi, S., additional, Roselli, J., additional, Mazzuoli, S., additional, Geccherle, A., additional, Soriano, A., additional, Principi, M.B., additional, Viola, A., additional, Sarpi, L., additional, Cappello, M., additional, D'Incà, R., additional, Mastronardi, M., additional, Bodini, G., additional, Guerra, M., additional, Benedetti, A., additional, Romano, M., additional, Cicala, M., additional, Sabatino, A. Di, additional, Scaldaferri, F., additional, De Rosa, T., additional, Giardino, A.M., additional, Germano, V., additional, Orlando, A., additional, and Armuzzi, A., additional

Published
2023
Full Text
View/download PDF

25. T.06.2 USTEKINUMAB IS A PROMISING OPTION FOR THE TREATMENT OF POSTOPERATIVE RECURRENCE OF CROHN'S DISEASE

Author

Macaluso, F.S., primary, Grova, M., additional, Mocciaro, F., additional, Di Mitri, R., additional, Privitera, A., additional, Distefano, M., additional, Vitello, A., additional, Camilleri, S., additional, Ferracane, C., additional, Pluchino, D., additional, Belluardo, N., additional, Giangreco, E., additional, Fries, W., additional, Viola, A., additional, Cappello, M., additional, D'Amato, L., additional, Bertolami, C., additional, Ventimiglia, M., additional, Renna, S., additional, Casa, A., additional, De Vivo, S., additional, and Orlando, A., additional

Published
2023
Full Text
View/download PDF

26. T.10.1 SAFETY AND EFFECTIVENESS OF TOFACITINIB IN ULCERATIVE COLITIS: REAL-WORLD DATA FROM TOFA-UC, A SN-IBD STUDY

Author

Macaluso, F.S., primary, D'Antonio, E., additional, Fries, W., additional, Viola, A., additional, Ksissa, O., additional, Cappello, M., additional, Muscarella, S., additional, Belluardo, N., additional, Giangreco, E., additional, Mocciaro, F., additional, Di Mitri, R., additional, Ferracane, C., additional, Vitello, A., additional, Grova, M., additional, Renna, S., additional, Casa, A., additional, Ventimiglia, M., additional, and Orlando, A., additional

Published
2023
Full Text
View/download PDF

31. Effectiveness and safety of vedolizumab in a matched cohort of elderly and nonelderly patients with inflammatory bowel disease: the IG-IBD LIVE study

Author

Pugliese, D., Privitera, G., Crispino, F., Mezzina, N., Castiglione, F., Fiorino, G., Laterza, L., Viola, A., Bertani, L., Caprioli, F., Cappello, M., Barberio, B., Ricci, C., Balestrieri, P., Daperno, M., Pluchino, D., Rizzello, F., Scribano, M. L., Sablich, R., Pastorelli, L., Manguso, F., Variola, A., Di Sario, A., Grossi, L., Armuzzi, A., Ribaldone, D. G., Biscaglia, G., Buda, A., Mocci, G., Viscido, A., Di Paolo, M. C., Onali, S., Rodino, S., Coletta, M., Principi, M., Miranda, A., Amato, A., Bezzio, C., Petruzzellis, C., Mazzuoli, S., Festa, S., Sartini, A., Checchin, D., Fanigliulo, L., Gallina, S., Cesarini, M., Bodini, G., Stradella, D., Spagnuolo, R., Guidi, L., Savarino, E., Scrivo, B., Soru, P., Costa, F., Fries, W., Scaldaferri, F., Allocca, M., Pellegrini, L., Massari, A., Orlando, A., Pugliese D., Privitera G., Crispino F., Mezzina N., Castiglione F., Fiorino G., Laterza L., Viola A., Bertani L., Caprioli F., Cappello M., Barberio B., Ricci C., Balestrieri P., Daperno M., Pluchino D., Rizzello F., Scribano M.L., Sablich R., Pastorelli L., Manguso F., Variola A., Di Sario A., Grossi L., Armuzzi A., Ribaldone D.G., Biscaglia G., Buda A., Mocci G., Viscido A., Di Paolo M.C., Onali S., Rodino S., Coletta M., Principi M., Miranda A., Amato A., Bezzio C., Petruzzellis C., Mazzuoli S., Festa S., Sartini A., Checchin D., Fanigliulo L., Gallina S., Cesarini M., Bodini G., Stradella D., Spagnuolo R., Guidi L., Savarino E., Scrivo B., Soru P., Costa F., Fries W., Scaldaferri F., Allocca M., Pellegrini L., Massari A., and Orlando A.

Subjects
Crohn’s disease, Ulcerative, Antibodies, Monoclonal, Humanized, biologics (IBD), immunosuppression, ulcerative colitis, Aged, Chronic Disease, Colitis, Ulcerative, Crohn Disease, Humans, Prospective Studies, Retrospective Studies, Treatment Outcome, Tumor Necrosis Factor Inhibitors, Gastrointestinal Agents, Inflammatory Bowel Diseases, Antibodies, Monoclonal, Pharmacology (medical), Humanized, Settore MED/12 - Gastroenterologia, Hepatology, Gastroenterology, Colitis
Abstract

Background: Vedolizumab registration trials were the first to include elderly patients with moderate-to-severe ulcerative colitis (UC) or Crohn’s disease (CD), but few real-life data have been reported in this population. Aims: We investigated the effectiveness and safety of vedolizumab in matched cohorts of elderly and nonelderly UC and CD patients. Methods: The Long-term Italian Vedolizumab Effectiveness (LIVE) study is a retrospective-prospective study including UC and CD patients who started vedolizumab from April 2016 to June 2017. Elderly patients (≥65 years) were matched clinically 1:2 to nonelderly patients (18–64 years); the 2 groups were followed until drug discontinuation or June 2019. Results: The study included 198 elderly (108 UC, 90 CD) and 396 matched nonelderly patients (205 UC, 191 CD). Nonelderly UC patients had a significantly higher persistence on vedolizumab compared to elderly patients (67.6% vs. 51.4%, p=0.02). No significant difference in effectiveness was observed between elderly and nonelderly CD patients (59.4% vs. 52.4%, p=0.32). Age ≥65 years was associated with lower persistence in UC; for CD, previous exposure to anti-TNF-α agents, Charlson comorbidity index >2 and moderate-to-severe clinical activity at baseline were associated with lower persistence. There were recorded 130 adverse events, with comparable rates between the two groups. A Charlson comorbidity index >2 was associated with an increased risk of adverse events. Conclusion: Vedolizumab can be considered a safe option in elderly IBD patients. Its effectiveness in elderly UC patients may be reduced, while no age-dependent effect on effectiveness was observed in CD.

Published
2022

32. GIUDICI, ZANZOTTO, RABONI. AUTONOMIE ED ETERONOMIE DELLA PROSA

Author

Cappello, M.

Subjects
Settore L-FIL-LET/14 - Critica Letteraria e Letterature Comparate, Giovanni Giudici, Andrea Zanzotto, Giovanni Raboni, saggistica, poesia del secondo Novecento, Settore L-FIL-LET/11 - Letteratura Italiana Contemporanea
Published
2022

34. Effectiveness of adalimumab for ulcerative colitis: A multicentre, retrospective study of clinical practice in Italy

Author

Vitello, A, Grova, M, Pugliese, D, Rizzello, F, Lanzarotto, F, Lavagna, A, Caccaro, R, Cappello, M, Viola, A, Ribaldone, Dg, Principi, M, Stasi, E, Scribano, Ml, Maida, M, Soriano, A, Bezzio, C, Bodini, G, Mocciaro, F, Privitera, Ac, Simondi, D, Giuffrida, E, D'Incà, R, Ricci, C, Gionchetti, P, Armuzzi, A, Orlando, A, Daperno, M, Italian Group for the Study of Inflammatory Bowel Disease (IG-IBD, Vitello A., Grova M., Pugliese D., Rizzello F., Lanzarotto F., Lavagna A., Caccaro R., Cappello M., Viola A., Ribaldone D.G., Principi M., Stasi E., Scribano M.L., Maida M., Soriano A., Bezzio C., Bodini G., Mocciaro F., Privitera A.C., Simondi D., Giuffrida E., D'Inca R., Ricci C., Gionchetti P., Armuzzi A., Orlando A., and Daperno M.

Subjects
musculoskeletal diseases, Adult, Male, medicine.medical_specialty, Adolescent, medicine.medical_treatment, Effectiveness, Young Adult, Internal medicine, Adalimumab, Medicine, Humans, Adverse effect, skin and connective tissue diseases, Colectomy, Aged, Retrospective Studies, Real-world evidence, Hepatology, business.industry, Gastroenterology, Effectivene, Retrospective cohort study, Induction Chemotherapy, Middle Aged, medicine.disease, Ulcerative colitis, Discontinuation, Clinical Practice, Treatment Outcome, Italy, Safety, Concomitant, Colitis, Ulcerative, Female, Tumor Necrosis Factor Inhibitors, business, medicine.drug
Abstract

Background Adalimumab is used to treat ulcerative colitis, but additional effectiveness and safety data are needed. Patients and methods This retrospective study considered adults with ulcerative colitis treated with adalimumab at 19 hospitals. Clinical data were collected from the start of treatment, after 2, 6 and 12 months, and at the last visit. Outcome measures of effectiveness were treatment duration, reasons for discontinuation and colectomy. Results We studied 381 patients treated with adalimumab for a median of 12.1 months. Disease activity at the start of treatment was moderate to severe in 262 cases (68.8%) and endoscopic activity was moderate to severe in 339 cases (89.0%). At week 8, clinical responses were observed in 177 cases (46.5%) and clinical remission in 136 cases (35.7%). At 12 months, remission was observed in 128 cases (33.6%). Overall, 44 patients required colectomy, and 170 patients (44.6%) were still taking adalimumab when data were collected. Variables associated with adalimumab discontinuation were concomitant steroid treatment, severe clinical-endoscopic activity at baseline, need for adalimumab intensification and drug-related adverse events. Variables associated with colectomy were concomitant steroid treatment and high baseline C-reactive protein. Conclusion Adalimumab is safe and effective for the treatment of ulcerative colitis.

Published
2021

35. Clinical and prognostic relevance of sST2 in adults with dengue-associated cardiac impairment and severe dengue

Author

Cappello, M, Teo, A, Chia, PY, Ramireddi, GK, Khoo, SKM, Yeo, TW, Cappello, M, Teo, A, Chia, PY, Ramireddi, GK, Khoo, SKM, and Yeo, TW

Abstract

BACKGROUND: Dengue can be complicated by severe outcomes including cardiac impairment, and the lack of reliable prognostic biomarkers poses a challenge in managing febrile dengue patients. Here, we investigated the functionality of soluble suppressor of tumorigenicity (sST2) as a predictive marker of severe dengue and its association in dengue-associated cardiac impairment. METHODS: Plasma samples, aged >16 years, collected from 36 dengue fever, 43 dengue with warning signs, 11 severe dengue (collected at febrile, critical and recovery phases) and 30 controls were assayed for plasma levels of sST2, troponin T and N-terminal (NT)-pro hormone brain natriuretic peptide (NT-proBNP) by ELISA. Cardiac parameters: stroke index (SI), cardiac index (CI) and Granov-Goor Index (GGI) were measured with a bioimpedance device during the different phases for dengue subjects and once for the controls. PRINCIPAL FINDINGS: In the febrile, critical and early recovery phases, sST2 levels were significantly elevated in dengue participants and sST2 levels increased with increasing disease severity (P < 0.01 for all). sST2 concentrations were negatively correlated with SI (r = -0.48; P < 0.001, r = -0.55; P < 0.001), CI (r = -0.26; P = 0.02, r = -0.6: P < 0.001) and GGI (r = -0.44; P < 0.001, r = -0.57; P < 0.001) in the critical and early recovery phases. In contrast, sST2 levels in the febrile and critical phases, were positive correlated to troponin T (r = 0.44, P < 0.001; r = 0.22, P = 0.03, respectively) and NT-proBNP (r = 0.21, P = 0.03; r = 0.35, P < 0.001). ROC analysis demonstrated sST2 as a good biomarker of severe dengue in the critical phase, AUROC 0.79, P < 0.001. CONCLUSION/SIGNIFICANCE: sST2 levels were elevated in patients with dengue especially in cases of severe dengue. Furthermore, increased sST2 levels were associated with cardiac indicators suggesting lower cardiac performance. While further research is needed to demonstrate its clinical utility, sST2 may be a useful

Published
2022

38. P412 The Sicilian network of biological therapy in inflammatory bowel disease: preliminary data on efficacy

Author

Orlando, A., Macaluso, F.S., Fries, W., Privitera, A.C., Cappello, M., Siringo, S., Inserra, G., Magnano, A., Di Mitri, R., Belluardo, N., Scarpulla, G., Magrì, G., Trovatello, N., Carroccio, A., Genova, S., Calandruccio, G., Vassallo, R., Romano, C., Pellegrino, S., Citrano, M., Accomando, S., Ventimiglia, M., Renna, S., Orlando, R., Rizzuto, G., Vinci, E., and Cottone, M.

Published
2017
Full Text
View/download PDF

39. OP005 The PROSIT cohort of infliximab biosimilar in IBD: a prolonged follow-up on the efficacy and safety across Italy

Author

Guidi, L., Fiorino, G., Variola, A., Manetti, N., Fries, W., Rizzuto, G., Bossa, F., Cappello, M., Biancone, L., DʼIncà, R., Cantoro, L., Castiglione, F., Principi, M., Annunziata, M.L., Di Girolamo, M., Terpin, M.M., Cortelezzi, C.C., Costa, F., Amato, A., Di Sabatino, A., Saibeni, S., Meucci, G., Petruzzellis, C., Tari, R., Gugliemi, F.W., Armuzzi, A., Danese, S., Geccherle, A., Rogai, F., Ventra, A., Orlando, A., Andriulli, A., Scrivo, B., Troncone, E., Caccaro, R., Kohn, A., Nardone, O., and Annese, V.

Published
2017
Full Text
View/download PDF

42. T.06.2 MANAGEMENT AND OUTCOME OF CHECK-POINT INHIBITORINDUCED COLITIS: A MULTICENTRE RETROSPECTIVE STUDY

Author

Lenti, M.V., primary, Ribaldone, D.G., additional, Vernero, M., additional, De Andreis, F. Borrelli, additional, Savarino, E., additional, Zingone, F., additional, Sottotetti, F., additional, Cappello, M., additional, Brinch, D., additional, Silvestris, N., additional, Rossi, C.M., additional, Santacroce, G., additional, Klersy, C., additional, De Grazia, F., additional, Pagani, A., additional, Muscarella, S., additional, Brunetti, O., additional, De Ruvo, M., additional, Premoli, A., additional, Pedrazzoli, P., additional, Corazza, G.R., additional, and Di Sabatino, A., additional

Published
2022
Full Text
View/download PDF

44. T.06.8 COMPARATIVE OBJECTIVE EFFECTIVENESS OF VEDOLIZUMAB AND USTEKINUMAB IN A REAL-LIFE COHORT OF ACTIVE CROHN’S DISEASE PATIENTS FAILURE TO TNF INHIBITORS

Author

Onali, S., primary, Pugliese, D., additional, Caprioli, F.A., additional, Orlando, A., additional, Biancone, L., additional, Nardone, O.M., additional, Imperatore, N., additional, Fiorino, G., additional, Cappello, M., additional, Viola, A., additional, Principi, M.B., additional, Bezzio, C., additional, Aratari, A., additional, Carparelli, S., additional, Mancuso, F., additional, Grossi, L., additional, Bodini, G., additional, Ribaldone, D., additional, Mocci, G., additional, Favale, A., additional, Grova, M., additional, Scucchi, L., additional, Segato, S., additional, Fries, W., additional, Castiglione, F., additional, Armuzzi, A., additional, and Fantini, M.C., additional

Published
2022
Full Text
View/download PDF

46. T.06.10 EFFICACY AND SAFETY OF BIOSIMILARS OF ANTI-TNF-APLHA IN PAEDIATRIC-ONSET INFLAMMATORY BOWEL DISEASE: DATA FROM THE SICILIAN NETWORK FOR INFLAMMATORY BOWEL DISEASES (SN-IBD)

Author

Dipasquale, V., primary, Pellegrino, S., additional, Ventimiglia, M., additional, Cucinotta, U., additional, Citrano, M., additional, Graziano, F., additional, Cappello, M., additional, Busacca, A., additional, Orlando, A., additional, Accomando, S., additional, and Romano, C., additional

Published
2022
Full Text
View/download PDF

47. OC.10.3 THE EFFECTIVENESS OF USTEKINUMAB AND VEDOLIZUMAB AS THIRD-LINE THERAPY IN PATIENTS WITH REFRACTORY CROHN’S DISEASE

Author

Macaluso, F.S., primary, Grova, M., additional, Saladino, M., additional, Demarzo, M.G., additional, Privitera, A.C., additional, Giangreco, E., additional, Garufi, S., additional, Renna, S., additional, Casà, A., additional, Ventimiglia, M., additional, Cappello, M., additional, Fries, W., additional, and Orlando, A., additional

Published
2022
Full Text
View/download PDF

50. IBD and Covid-19 in Italy: comparisons between first and second pandemic wave

Author

Bezzio, C., Costa, S., Armuzzi, A., Furfaro, F., Ardizzone, S., Milla, M., Bossa, F., Orlando, A., Caprioli, F. A., Castiglione, F., Vigano, C., Ribaldone, D. G., Zingone, F., Monterubbianesi, R., Imperatore, N., Festa, S., Daperno, M., Scucchi, L., Ferronato, A., Pastorelli, L., Balestrieri, P., Ricci, C., Cappello, M., Felice, C., Coppini, F., Alvisi, P., Gerardi, V., Variola, A., Mazzuoli, S., Lenti, M. V., Alessandro Armuzzi, Buda, A., Micheli, F., Ciardo, V., Casella, G., Viscido, A., Bodini, G., Fiorino, G., Vernero, M., and Saibeni, S.

Subjects
covid-19, inflammatory bowel disease, outcomes
Published
2022

Catalog

Books, media, physical & digital resources
See catalog results